JNJJanssen Research & Development, LLCRunning, no new patients
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Lymphoma, Non-Hodgkin · Lymphoma, B-Cell · Lymphoma, Large B-Cell, Diffuse
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 1/2
- Patients
- 166 (final count)
- Started
- Aug 12, 2022
- Main results expected
- Jul 30, 2041
- Fully finished
- Jul 30, 2041
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1b: Occurrence of Adverse Events (AEs) [Safety and Tolerability]
Measured over: Up to 15 Years post JNJ-90014496 infusion
Phase 2: Overall Response (OR) As Assessed by Independent Review Committee (IRC)
Measured over: Up to 6 months post last participant's JNJ-90014496 infusion
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05421663 · record last updated 2026-11-03 · checked 2026-11-09 15:42 UTC